Table 2.

Sensitivity analysis of benefit-risk over control: ixazomib plus lenalidomide plus dexamethasone

		Range of variation				Basis of selection of range
Decision factor	Parameter	Low	Expected	High	Factor	Detail
Benefit	Estimated PFS improvement [months]	4.42	5.90	7.38	Population heterogeneity	Variation in estimated PFS of Ixazomib and Control corresponding to ± 50% variation in proportion of population with no prior stem cell transplant (± 0.45 months for Ixazomib and ± 1.41 months for Control)
Risk Death	Severity [months]	36.86	39.81	42.76	Natural history	Variation in life expectancy for Control corresponding to ± 50% variation in proportion of population with stem cell transplant (± 2.95 months)
	Occurrence relative to control	−0.037	−0.014	0.009	Exposure	Attributability to treatment (± 50% of occurrence adjusted for treatment duration)
		−0.037	−0.014	0.009	Attributability	Attributability to treatment (± 50% of occurrence adjusted for treatment duration)
Nonfatal serious AEs	Severity [months]	0.88	1.32	2.62	Estimation of seriousness	Variation of ± 1/2 grade of severity of AE
	Occurrence relative to control	−0.347	−0.047	0.253	Exposure	Attributability to treatment (± 50% of occurrence adjusted for treatment duration)
		−0.347	−0.047	0.253	Attributability	Attributability to treatment (± 50% of occurrence adjusted for treatment duration)
Common AEs	Severity [months]	0.1045	0.1479	0.2779	Estimation of seriousness	Variation of ± 1/2 grade of severity of AE
	Occurrence relative to control	−1.000	−1.680	−1.227	Exposure	Attributability to treatment (± 50% of occurrence adjusted for treatment duration)
		−1.000	−1.680	−1.295	Attributability	Attributability to treatment (± 50% of occurrence adjusted for treatment duration)